Bromocriptine

Revision as of 21:36, 19 September 2019 by ClaireLewis (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Administration

  • Type: Dopamine agonist
  • Dosage Forms: capsule, tablet
  • Dosage Strengths: capsule: 5mg; tablet: 0.8, 2.5mg
  • Routes of Administration: PO
  • Common Trade Names: Parlodel, Cycloset

Adult Dosing

  • Acromegaly
    • 20-30 mg PO QD
      • Start: 1.25-2.5 mg PO qhs x3 days
        • Increase by 1.25-2.5 mg per day q 3-7 days
      • Max: 100 mg per day
      • Give with food and taper dose to D/C
  • Hyperprolactinemia
    • 2.5-15 mg PO QD
      • Start: 1.5-2.5 mg PO QD
        • Increase by 1.25-2.5 mg per day q 2-7 days
      • Give with food and taper dose to D/C
  • Parkinson's disease
    • 10-30 mg PO tid
      • Max: 100 mg/day
      • Give with food and taper dose to D/C
  • Neuroleptic malignant syndrome
    • 5-10 mg PO tid-QID
      • Start: 2.5 mg PO tid-QID
        • Increase dose as tolerated
      • Max: 20 mg PO QID
      • Continue x7-10 days, then taper dose over 3 days to D/C

Pediatric Dosing

  • Adenoma, prolactin-secreting
    • 11-15 yo
      • 2.5-10 mg PO QD
        • Start: 1.25-2.5 mg PO QD
        • Give with food and taper dose to D/C
    • 16+ yo
      • 2.5-15 mg PO QD
        • Start: 1.25-2.5 mg PO QD
        • Give with food and taper dose to D/C

Special Populations

  • Pregnancy Rating: B; No known risk of fetal harm based on human data. Monitor hyperprolactinemic pts closely for potential prolactin-secreting tumor enlargement.
  • Lactation risk: L5; Contraindicated in postpartum lactation

Renal Dosing

  • Adult: Not defined. Caution advised.
  • Pediatric: Not defined. Caution advised.

Hepatic Dosing

  • Adult: Not defined. Caution advised.
  • Pediatric: Not defined. Caution advised.

Contraindications

  • Allergy to class/drug
  • Hypersensitivity to ergot derivatives
  • Hypertension, uncontrolled
  • Breastfeeding
  • Avoid abrupt withdrawal

Adverse Reactions

Serious

Common

Pharmacology

  • Half-life: Biphasic 4-4.5 hr and 15 hr
  • Metabolism: Liver; CYP450: 3A4 substrate
  • Excretion: Bile 95%, urine 2.5-5.5%

Mechanism of Action

  • Stimulates dopamine receptors
  • Inhibits anterior pituitary prolactin secretion

Comments

See Also

References